Fulgent Genetics (NASDAQ:FLGT – Get Rating) had its price objective trimmed by Credit Suisse Group from $50.00 to $45.00 in a research report report published on Thursday morning, The Fly reports. The firm currently has an outperform rating on the stock.
Several other research analysts also recently weighed in on FLGT. Piper Sandler downgraded shares of Fulgent Genetics from an overweight rating to a neutral rating and decreased their target price for the company from $65.00 to $40.00 in a research note on Thursday, December 8th. Raymond James initiated coverage on shares of Fulgent Genetics in a research note on Friday, November 18th. They set an outperform rating and a $45.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Fulgent Genetics has a consensus rating of Moderate Buy and a consensus price target of $43.33.
Fulgent Genetics Trading Up 1.0 %
Shares of FLGT stock opened at $33.74 on Thursday. The company has a market capitalization of $996.00 million, a PE ratio of 7.40 and a beta of 1.61. The firm has a fifty day simple moving average of $32.36 and a 200-day simple moving average of $36.40. Fulgent Genetics has a twelve month low of $28.53 and a twelve month high of $65.32.
Institutional Trading of Fulgent Genetics
A number of large investors have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Fulgent Genetics by 4.5% in the 3rd quarter. BlackRock Inc. now owns 3,484,339 shares of the company’s stock worth $132,825,000 after acquiring an additional 149,014 shares during the period. Vanguard Group Inc. increased its holdings in shares of Fulgent Genetics by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,365,736 shares of the company’s stock worth $52,062,000 after acquiring an additional 32,173 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Fulgent Genetics by 17.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 798,326 shares of the company’s stock worth $23,776,000 after acquiring an additional 117,504 shares during the period. State Street Corp increased its stake in Fulgent Genetics by 5.3% during the 3rd quarter. State Street Corp now owns 756,357 shares of the company’s stock valued at $28,832,000 after buying an additional 38,121 shares during the period. Finally, Park West Asset Management LLC increased its stake in Fulgent Genetics by 152.0% during the 2nd quarter. Park West Asset Management LLC now owns 629,882 shares of the company’s stock valued at $34,347,000 after buying an additional 379,882 shares during the period. Institutional investors and hedge funds own 43.22% of the company’s stock.
About Fulgent Genetics
Fulgent Genetics, Inc is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.
Featured Stories
Receive News & Ratings for Fulgent Genetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fulgent Genetics and related companies with MarketBeat.com’s FREE daily email newsletter.